Literature DB >> 2743088

A comparison of the effects of a series of anti-anginal agents in a novel canine model of transient myocardial ischaemia.

M C Allely1, B J Alps.   

Abstract

1. An anaesthetized canine model of transient myocardial ischemia (TMI) has been developed in which reproducible and reversible electrocardiographic (ECG) and haemodynamic responses are exacerbated by electrical pacing. 2. The model could separate the ECG and haemodynamic effects of compounds with anti-ischaemic properties. 3. Compounds known to possess peripheral or coronary vasodilator properties did not necessarily alleviate the ECG consequences of TMI since glyceryl trinitrate was active whereas dipyridamole was not. The effects of verapamil were complicated by its adverse conduction effects while lidoflazine inhibited the ECG changes only during the ischaemic phase and the 'metabolic modulator' oxfenicine worsened the ECG response. 4. In a model considered to lack coronary reserve, improvements observed in the ischaemic ECG and global ventricular function were considered to result from a direct myocardial effect of the drugs examined rather than by a vascular influence. This was provided to the greatest degree by the Ca2+-entry blockers nifedipine and nicardipine, with flunarizine adopting an intermediate position.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2743088      PMCID: PMC1854441          DOI: 10.1111/j.1476-5381.1989.tb11910.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Simultaneous assessment of effects of coronary vasodilators on the coronary blood flow and the myocardial contractility by using the blood-perfused canine papillary muscle.

Authors:  N Himori; H Ono; N Taira
Journal:  Jpn J Pharmacol       Date:  1976-08

2.  Differential response of large and small coronary arteries to nitroglycerin and angiotensin. Autoregulation and tachyphylaxis.

Authors:  M V Cohen; E S Kirk
Journal:  Circ Res       Date:  1973-10       Impact factor: 17.367

3.  Lidoflazine: a new drug in the treatment of angina pectoris.

Authors:  V Bernstein; D I Peretz
Journal:  Curr Ther Res Clin Exp       Date:  1972-08

4.  Tissue specificity of calcium-antagonistic properties of lidoflazine.

Authors:  J M Van Nueten; D Wellens
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-12

5.  Effect of nitroglycerin and dipyridamole on regional left ventricular blood flow during coronary artery occlusion.

Authors:  L C Becker
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

6.  Mechanism of action of oxfenicine on muscle metabolism.

Authors:  A J Higgins; M Morville; R A Burges; K J Blackburn
Journal:  Biochem Biophys Res Commun       Date:  1981-05-15       Impact factor: 3.575

7.  The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog.

Authors:  M C Allely; B J Alps
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

8.  The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator.

Authors:  W K Schaper; R Xhoneux; A H Jageneau; P A Janssen
Journal:  J Pharmacol Exp Ther       Date:  1966-05       Impact factor: 4.030

9.  Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay k 5552), a new dihydropyridine calcium antagonist.

Authors:  D C Warltier; C M Meils; G J Gross; H L Brooks
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

10.  Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris.

Authors:  L Szekeres; V Csik; E Udvary
Journal:  J Pharmacol Exp Ther       Date:  1976-01       Impact factor: 4.030

View more
  4 in total

1.  F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models.

Authors:  B Vacher; C Pignier; R Létienne; Y Verscheure; B Le Grand
Journal:  Br J Pharmacol       Date:  2009-01-07       Impact factor: 8.739

2.  Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.

Authors:  D Jain; P Dasgupta; L O Hughes; A Lahiri; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine.

Authors:  L Belardinelli; J C Shryock; H Fraser
Journal:  Heart       Date:  2006-07       Impact factor: 5.994

4.  Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase.

Authors:  B Clarke; M Spedding; L Patmore; J G McCormack
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.